EU and US Establish Joint AI Principles for Medicines Industry

Jan 20, 2026, 2:38 AM

Health Medicine Research Innovation Tech US

Image for article EU and US Establish Joint AI Principles for Medicines Industry

Hover over text to view sources

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly established ten principles aimed at guiding the use of artificial intelligence (AI) in the medicines industry. This landmark initiative seeks to reduce regulatory divergence between the European Union and the United States, thereby enhancing cooperation and innovation in drug development.

The principles emphasize a human-centric approach to AI, advocating for risk-aware practices, adherence to defined standards, and the necessity of multidisciplinary expertise in overseeing AI technologies. They also stress the importance of clear data governance, documentation, and the use of plain language to communicate AI's capabilities and limitations to relevant stakeholders.

Nils Rauer, an AI expert with Pinsent Masons, noted that while these principles provide high-level guidance, more detailed frameworks will be necessary for practical implementation. He highlighted the alignment between these principles and the EU's AI Act, particularly regarding risk-based approaches and the significance of data governance.

The joint principles were developed following a bilateral meeting between EU health officials and the FDA in April 2024, reflecting a growing recognition of the need for international cooperation in AI regulation. Catherine Drew, a life sciences specialist, emphasized that this collaboration is crucial for ensuring that the development and approval of medicines keep pace with technological advancements, particularly in AI.

The principles cover the entire lifecycle of drug development, from early-stage discovery to post-market safety monitoring. They aim to dismantle the so-called "AI black box," which often obscures the processes behind AI-generated results. The EMA and FDA expect pharmaceutical companies to provide clear explanations of AI's limitations and the data used, ensuring that patient safety and ethical integrity remain paramount.

Industry associations have welcomed this initiative, viewing it as a significant step toward global regulatory convergence. The European Federation of Pharmaceutical Industries and Associations (EFPIA) expressed support for the EMA and FDA's collaborative efforts, noting that the principles create a foundation for a unified language in medical technology development.

Despite the positive reception, experts caution that the principles are still high-level and require further elaboration. The EMA and FDA's guidance does not fundamentally alter existing AI practices in the pharmaceutical industry but sets the stage for more detailed regulations and standards in the future.

As AI technologies become increasingly integrated into drug development processes, the need for robust regulatory frameworks is more pressing than ever. The EMA and FDA's joint principles represent a proactive approach to managing the risks associated with AI while harnessing its potential to accelerate the development of safe and effective medicines.

In conclusion, the establishment of these joint AI principles marks a significant milestone in the collaboration between the EU and the US in the field of medicine. By fostering a harmonized regulatory environment, both agencies aim to enhance patient safety and promote innovation in the pharmaceutical sector, ultimately benefiting patients worldwide.

EMA and FDA Establish Joint Principles for AI in Medicine

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly established ten principles to guide the responsible use of artificial intelligence (AI) in the development of medicines. This initiative aims to enhance collaboration between regulators and improve the safety and efficacy of medical products.

NVIDIA and Natera Collaborate on AI for Precision Medicine

NVIDIA and Natera have announced a collaboration to enhance AI foundation models for precision medicine. This partnership aims to leverage Natera's extensive datasets and NVIDIA's computing power to improve diagnostics and personalized therapies.

OpenAI and Anthropic Target Health Care for AI Expansion

OpenAI and Anthropic are positioning themselves to leverage AI in the health care sector, aiming to integrate health data into existing platforms rather than creating new applications. This strategy capitalizes on their established user bases and the evolving health care infrastructure.

Insilico Medicine's IPO Fuels AI-Driven Drug Discovery Success

Insilico Medicine has made headlines by successfully launching its IPO in Hong Kong, raising approximately $293 million. The company has quickly advanced its AI-driven drug candidate, rentosertib, into phase 2 trials for idiopathic pulmonary fibrosis, showcasing the potential of AI in accelerating drug discovery.

'90s Video Games Like 'Mario Kart' Boost Children's Brain Health, Claims Counselor

Mental health counselor Veronica Lichtenstein argues that video games from the 1990s, such as 'Mario Kart,' positively impacted children's cognitive development and mental health. In contrast, modern games are designed to promote addiction and lack the critical thinking challenges that older games provided.